Chitosan oligosaccharides inhibit/disaggregate fibrils and attenuate amyloid β-mediated neurotoxicity

International Journal of Molecular Sciences

Volumn 16, Issue 5, 2015, Pages 10526-10536

  Dai, Xueling ^a   Hou, Wanqi ^b   Sun, Yaxuan ^a   Gao, Zhaolan ^a   Zhu, Shigong ^c   Jiang, Zhaofeng ^a  

^a BEIJING UNION UNIVERSITY   (China)

^b CAPITAL NORMAL UNIVERSITY   (China)

^c PEKING UNIVERSITY HEALTH SCIENCE CENTER   (China)

Author keywords

Aggregation; Alzheimer s disease; Amyloid peptide; Chitosan oligosaccharides; Neurotoxicity

Indexed keywords

AMYLOID BETA PROTEIN; CHITOSAN OLIGOSACCHARIDE; OLIGOSACCHARIDE; THIOFLAVINE; UNCLASSIFIED DRUG; AMYLOID BETA-PROTEIN (1-42); CHITOSAN; NEUROPROTECTIVE AGENT; PEPTIDE FRAGMENT; PROTEIN AGGREGATE;

ALZHEIMER DISEASE; ANIMAL CELL; APOPTOSIS; ARTICLE; CELL DISRUPTION; CELL VIABILITY; CIRCULAR DICHROISM; CONTROLLED STUDY; EMBRYO; FLOW CYTOMETRY; MTT ASSAY; NEUROTOXICITY; NONHUMAN; OXIDATIVE STRESS; PROTEIN SECONDARY STRUCTURE; RAT; TRANSMISSION ELECTRON MICROSCOPY; ANALOGS AND DERIVATIVES; ANIMAL; ANTAGONISTS AND INHIBITORS; CELL CULTURE; CELL SURVIVAL; CHEMISTRY; DRUG EFFECTS; METABOLISM; NERVE CELL; PATHOLOGY; PROTEIN AGGREGATION, PATHOLOGICAL; SPRAGUE DAWLEY RAT; ULTRASTRUCTURE;

RATTUS;

AMYLOID BETA-PEPTIDES; ANIMALS; CELL SURVIVAL; CELLS, CULTURED; CHITOSAN; NEURONS; NEUROPROTECTIVE AGENTS; OLIGOSACCHARIDES; PEPTIDE FRAGMENTS; PROTEIN AGGREGATES; PROTEIN AGGREGATION, PATHOLOGICAL; RATS; RATS, SPRAGUE-DAWLEY;

EID: 84929353020     PISSN: 16616596     EISSN: 14220067     Source Type: Journal    
DOI: 10.3390/ijms160510526     Document Type: Article

References (28)

1. Medeiros, R.; Baglietto-Vargas, D.; LaFerla, F.M. The role of tau in Alzheimer’s disease and related disorders. CNSNeurosci. Ther. 2011, 17, 514-524.
2. Ballard, C.; Gauthier, S.; Corbett, A.; Brayne, C.; Aarsland, D.; Jones, E. Alzheimer’s disease. Lancet 2011, 377, 1019-1031.
3. Selkoe, D.J. Preventing Alzheimer’s disease. Science 2012, 337, 1488-1492.
4. Walker, L.C.; Jucker, M. Amyloid by default. Nat. Neurosci. 2011, 14, 669-670.
5. Seltzer, B. Cholinesterase inhibitors in the clinical management of Alzheimer’s disease: Importance of early and persistent treatment. J. Int. Med. Res. 2006, 34, 339-347.
6. Van Marum, R.J. Current and future therapy in Alzheimer’s disease. Fundam. Clin. Pharmacol.2008, 22, 265-274.
7. Williams, P.; Sorribas, A.; Howes, M.J. Natural products as a source of Alzheimer’s drug leads. Nat. Prod. Rep. 2011, 28, 48-77.
8. Jana, S.; Sen, K.K.; Basu, S.K. Chitosan derivatives and their application in pharmaceutical fields. Int. J. Pharm. Res. 2011, 3, 1-8.
9. Liu, H.T.; Li, W.M.; Huang, P.; Chen, W.J.; Liu, Q.S.; Bai, X.F.; Yu, C.; Du, Y.G. Chitosan oligosaccharides inhibit TNF-a-induced VCAM-1 and ICAM-1 expression in human umbilical vein endothelial cells by blocking p38 and ERK1/2 signaling pathways. Carbohydr. Polym. 2010, 81, 49-56.
10. Fang, I.M.; Yang, C.H.; Yang, C.M.; Chen, M.S. Chitosan oligosaccharides attenuates oxidative-stress related retinal degeneration in rats. PLoS ONE 2013, 8, e77323.
11. Pangestuti, R.; Kim, S.-K. Marine-derived bioactive materials for neuroprotection. FoodSci. Biotechnol.2013, 22, 1-12.
12. Azuma, K.; Osaki, T.; Minami, S.; Okamoto, Y. Anticancer and anti-inflammatory properties of chitin and chitosan oligosaccharides. J. Funct. Biomater. 2015, 6, 33-49.
13. Dai, X.; Chang, P.; Zhu, Q.; Liu, W.; Sun, Y.; Zhu, S.; Jiang, Z. Chitosan oligosaccharides protect rat primary hippocampal neurons from oligomeric p-amyloid 1-42-induced neurotoxicity. Neurosci. Lett. 2013, 554, 64-69.
14. Petrlova, J.; Kalai, T.S.; Maezawa, I.; Altman, R.; Harishchandra, G.; Hong, H.-S.; Bricarello, D.A.; Parikh, A.N.; Lorigan, G.A.; Jin, L.-W.; et al. The influence of spin-labeled fluorene compounds on the assembly and toxicity of the Ap peptide. PLoS ONE 2012, 7, e35443.
15. Jiang, T.; Zhi, X.L.; Zhang, Y.H.; Pan, L.F.; Zhou, P. Inhibitory effect of curcumin on the Al(III)-induced Ap42 aggregation and neurotoxicity in vitro. Biochim. Biophys. Acta 2012, 1822, 1207-1215.
16. Jan, A.; Hartley, D.M.; Lashuel, H.A. Preparation and characterization of toxic Ap aggregates for structural and functional studies in Alzheimer’s disease research. Nat. Protoc. 2010, 5, 1186-1209.
17. Seeman, P.; Seeman, N. Alzheimer’s disease: p-Amyloid plaque formation in human brain. Synapse 2012, 65, 1289-1297.
18. Anand, R.; Gill, K.D.; Mahdi, A.A. Therapeutics of Alzheimer’s disease: Past, present and future. Neuropharmacology 2014, 76, 27-50.
19. Wang, Q.; Yu, X.; Patel, K.; Hu, R.; Chuang, S.S.; Zhang, G.; Zheng, J. Tanshinones inhibit amyloid aggregation by amyloid-p peptide, disaggregate amyloid fibrils, and protect cultured cells. ACS Chem. Neurosci. 2013, 19, 1004-1015.
20. Minicozzi, V.; Chiaraluce, R.; Consalvi, V.; Giordano, C.; Narcisi, C.; Punzi, P.; Rossi, G.C.; Morante, S. Computational and experimental studies on p-sheet breakers targeting Ap1-40 fibrils. J. Biol. Chem. 2014, 289, 11242-11252.
21. Ruggeri, F.S.; Adamcik, J.; Jeong, J.S.; Lashuel, H.A.; Mezzenga, R.; Dietler, G. Influence of the p-sheet content on the mechanical properties of aggregates during amyloid fibrillization. Angew. Chem. Int. Ed. Engl. 2015, 54, 2462-2466.
22. Liu, R.; Barkhordarian, H.; Emadi, S.; Park, C.B.; Sierks, M.R. Trehalose differentially inhibits aggregation and neurotoxicity of p-amyloid 40 and 42. Neurobiol. Dis. 2005, 20, 74-81.
23. Liu, F.-F.; Ji, L.; Dong, X.-Y.; Sun, Y. Molecular insight into the inhibition effect of trehalose on the nucleation and elongation of amyloid p-peptide oligomers. J. Phys. Chem. B 2009, 113, 11320-11329.
24. Benilova, I.; Karran, E.; de Strooper, B. The toxic Ap oligomer and Alzheimer’s disease: An emperor in need of clothes. Nat. Neurosci. 2012, 15, 349-357.
25. Yin, F.; Liu, J.; Ji, X.; Wang, Y.; Zidichouski, J.; Zhang, J. Silibinin: A novel inhibitor of Ap aggregation. Neurochem. Int. 2011, 58, 399-403.
26. Wang, S.W.; Wang, Y.J.; Su, Y.J.; Zhou, W.W.; Yang, S.G.; Zhang, R.; Zhao, M.; Li, Y.N.; Zhang, Z.P.; Zhan, D.W.; et al. Rutin inhibits p-amyloid aggregation and cytotoxicity, attenuates oxidative stress, and decreases the production of nitric oxide and proinflammatory cytokines. Neurotoxicology 2012, 33, 482-490.
27. Stine, W.B.; Dahlgren, K.N.; Krafft, G.A.; LaDu, M.J. In vitro characterization of conditions for amyloid-p peptide oligomerization and fibrillogenesis. J. Biol. Chem. 2003, 278, 11612-11622.
28. Dai, X.; Chang, P.; Liu, W.; Xu, K.; Sun, Y.; Zhu, S.; Jiang, Z. Ap-40 Y10F increases pfibrils formation but attenuates the neurotoxicity of amyloid-p peptide. Int. J. Mol. Sci. 2012, 13, 5324-5337.